BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34611846)

  • 1. Biomaterial-enabled induction of pancreatic-specific regulatory T cells through distinct signal transduction pathways.
    Carey ST; Gammon JM; Jewell CM
    Drug Deliv Transl Res; 2021 Dec; 11(6):2468-2481. PubMed ID: 34611846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting regulatory T cell expansion using polymer microparticles presenting defined ratios of self-antigen and regulatory cues.
    Bridgeman CJ; Shah SA; Oakes RS; Jewell CM
    Front Bioeng Biotechnol; 2023; 11():1184938. PubMed ID: 37441198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice.
    Koprivica I; Vujičić M; Gajić D; Saksida T; Stojanović I
    Front Immunol; 2018; 9():3130. PubMed ID: 30687329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally delivered all-trans-retinoic acid- and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice.
    Koprivica I; Gajic D; Saksida T; Cavalli E; Auci D; Despotovic S; Pejnovic N; Stosic-Grujicic S; Nicoletti F; Stojanovic I
    Eur J Pharmacol; 2019 Dec; 864():172721. PubMed ID: 31586630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
    Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
    Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype
    Brusko MA; Stewart JM; Posgai AL; Wasserfall CH; Atkinson MA; Brusko TM; Keselowsky BG
    Front Immunol; 2020; 11():574447. PubMed ID: 33193362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
    Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
    Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory Microparticles Epigenetically Modulate T Cells and Systemically Ameliorate Autoimmune Arthritis.
    McBride DA; Kerr MD; Johnson WT; Nguyen A; Zoccheddu M; Yao M; Prideaux EB; Dorn NC; Wang W; Svensson MND; Bottini N; Shah NJ
    Adv Sci (Weinh); 2023 Apr; 10(11):e2202720. PubMed ID: 36890657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
    Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
    Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and combined effect of retinoic acid and rapamycin modulate the generation, activity and homing potential of induced human regulatory T cells.
    Candia E; Reyes P; Covian C; Rodriguez F; Wainstein N; Morales J; Mosso C; Rosemblatt M; Fierro JA
    PLoS One; 2017; 12(7):e0182009. PubMed ID: 28746369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation.
    Verbeke CS; Gordo S; Schubert DA; Lewin SA; Desai RM; Dobbins J; Wucherpfennig KW; Mooney DJ
    Adv Healthc Mater; 2017 Mar; 6(6):. PubMed ID: 28116870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of Islet Engrafts via Treg Induction Using Immunomodulating Polymeric Tolerogenic Microparticles.
    Neshat SY; Bauer SJ; Rhodes KR; Quiroz VM; Wong VW; Lowmaster SM; Tzeng SY; Green JJ; Doloff JC
    ACS Biomater Sci Eng; 2023 Jun; 9(6):3522-3534. PubMed ID: 37233985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(2-propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles as a targeted antigen delivery system to direct either CD4
    Yang L; Bracho-Sanchez E; Fernando LP; Lewis JS; Carstens MR; Duvall CL; Keselowsky BG
    Bioeng Transl Med; 2017 Jun; 2(2):202-211. PubMed ID: 29313030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells.
    Gosselin EA; Tostanoski LH; Jewell CM
    AAPS J; 2017 Jul; 19(4):1175-1185. PubMed ID: 28484962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrest in the Progression of Type 1 Diabetes at the Mid-Stage of Insulitic Autoimmunity Using an Autoantigen-Decorated All-
    Phillips BE; Garciafigueroa Y; Engman C; Liu W; Wang Y; Lakomy RJ; Meng WS; Trucco M; Giannoukakis N
    Front Immunol; 2021; 12():586220. PubMed ID: 33763059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old Dog New Tricks: PLGA Microparticles as an Adjuvant for Insulin Peptide Fragment-Induced Immune Tolerance against Type 1 Diabetes.
    Liu M; Feng D; Liang X; Li M; Yang J; Wang H; Pang L; Zhou Z; Yang Z; Kong D; Li C
    Mol Pharm; 2020 Sep; 17(9):3513-3525. PubMed ID: 32787283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.
    Wang Y; Camirand G; Lin Y; Froicu M; Deng S; Shlomchik WD; Lakkis FG; Rothstein DM
    J Immunol; 2011 Mar; 186(5):2809-18. PubMed ID: 21270412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
    Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
    J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-Specific Treg Therapy in Type 1 Diabetes - Challenges and Opportunities.
    Serr I; Drost F; Schubert B; Daniel C
    Front Immunol; 2021; 12():712870. PubMed ID: 34367177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
    Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
    Front Immunol; 2021; 12():635767. PubMed ID: 33815387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.